International Journal of Medical and Health Sciences Research

Published by: Asian Medical Journals
Online ISSN: 2313-2752
Print ISSN: 2313-7746
Quick Submission    Login/Submit/Track

No. 5

Old Theories Revisited on Cancer Assistant Therapy

Pages: 50-57
Find References

Finding References


Old Theories Revisited on Cancer Assistant Therapy

Search :
Google Scholor
Search :
Microsoft Academic Search
Cite

Citation: 10

Da-Yong Lu , Ting-Ren Lu , Jin-Yu Che , Hong-Ying Wu

Export to    BibTeX   |   EndNote   |   RIS

  1. D. Lu, T. Lu, X. Chen, and J. Ding, Individualized cancer chemotherapy. Hypotheses in clinical medicine. Chapter No. 13. US: Nova Publisher, 2012.
  2. M. Mandala, G. Ferretti, M. Cremonesi, M. Cazzaniga, G. Curigliano, and S. Barni, "Venous thromboembolism and cancer: New issues for an old topic," Critical Rev in Oncology/Hematology, vol. 48, pp. 65-80, 2003.
  3. D. Lu, X. Chen, and J. Ding, "Treatment of solid tumors and metastases by fibrinogen-targeted anticancer drug therapy," Medical Hypotheses, vol. 68, pp. 188-193, 2007.
  4. G. Nash, L. Turner, M. Scully, and A. Kakkar, "Platelets and Cancer," Lancet Oncol, vol. 3, pp. 425-430  2002.
  5. D. Lu, X. Chen, M. Huang, B. Xu, and J. Ding, "Relationship between blood fibrinogen concentration and pathological features of cancer patients: A 139-case clinical study," OnLine Journal of Biological Sciences, vol. 7, pp. 8-11, 2007.
  6. D. Che, J. Cao, I. Shang, Y. Man, and Y. Yu, "The efficacy and safety of low-molecular-weight-heparin use for cancer treatment; a meta-analysis," Eur J Internal Medicine, vol. 24, pp. 433-439, 2013.
  7. D. Lu, J. Cao, Y. Huang, L. Gong, X. Chen, E. Chen, and B. Xu, "Comparison of some antineoplastic drugs on inhibiting thrombin catalyzing fibrinogen clotting in vitro," Chinese Medical Journal, vol. 112, pp. 1052-1053, 1999.
  8. D. Lu, J. Chi, L. Lin, M. Huang, B. Xu, and J. Ding, "Effect of anticancer drugs on the binding of 125I-fibrinogen to two leukemia cell lines in vitro," J. Int. Med. Res., vol. 32, pp. 488-491, 2004.
  9. D. Jonas, J. Evans, H. McLeod, S. Brode, L. Lange, M. Young, B. Shilliday, M. Bardsley, N. Swinton-Jenkins, and K. Weck, "Impact of genotype-guided dosing on anticoagulation visits for adults starting warfarin: A randomized controlled trial," Pharmacogenomics, vol. 14, pp. 1593-1603, 2013.
  10. J. Wereldsma, E. Bruggink, W. Meijer, J. Roukema, and W. Van Putten, "Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/ heparin verses urokinase versus control. Results of prospective randomized clinical trial (Colorectal Adenocarcinoma Trial I)," Cancer, vol. 65, pp. 425-432, 1990.
  11. V. Costantini and L. R. Zacharski, "The role of fibrin in tumor metastasis," Cancer Metastasis Rev., vol. 11, pp. 283-290, 1992.
  12. V. Bobek, "Anticoagulant and fibrinolytic drugs—possible agents in treatment of lung cancer?," Anticancer Agents in Medicinal Chemistry, vol. 12, pp. 580-588, 2012.
  13. T. Grint, A. Riley, S. Mills, B. Potter, and S. Safrany, "Fibrinogen—a possible extracellular target for inosital phosphates," Messenger, vol. 1, pp. 160-166 2012.
  14. S. Uppal, E. Hernandez, M. Dutta, V. Dandolu, and S. Rose, "Hartenbach E. Prolonged postoperative venous thrombo-embolism prophylaxis is cost-effective in advanced ovarian cancer patients," Gynecologic Oncology, vol. 127, pp. 631-637, 2012.
  15. J. Lieb, "Antidepressants, prostaglandins and the prevention and treatment of cancer," Med Hypotheses, vol. 69, pp. 684-689, 2007.
  16. D. Lu and T. Lu, "Antidepressants can be only used as assistant therapy in cancer treatment," Medical Hypotheses, vol. 70, pp. 204-205, 2008.
  17. M. Teicher, C. Glod, and J. Cole, "Emergence of intense suicidal preoccupation during fluoxetine treatment," Am J Psychiatry, vol. 147, pp. 207-210, 1990.
  18. D. Lu, T. Lu, and P. Zhu, "Undesired neural side-effects of a drug, a chemical and genetic interrelated problem," Central Nervous System Agents in Medicinal Chemistry, vol. 10, pp. 108-112, 2010.
  19. D. Lu and T. Lu, "Importance of genomic studies for drug withdrawal with mental toxicities," Drug Therapy Studies, vol. 1, p. e11, 2011.
  20. D. Lu, T. Lu, and P. Zhu, "How can we pinpoint genetic involvement in antidepressant-induced suicide?," Advances in Pharmacoepidemiology & Drug Safety, vol. 1, p. e101, 2012.
  21. D. Lu, T. Lu, and P. Zhu, "Pharmacogenetics in neural toxicities of drugs," Pharmacogenomics, vol. 14, pp. 1129-1131, 2013.
  22. The Emperor’s Medical Experience, Questions and Answers (????).
  23. G. Yang, X. Li, X. Li, L. Wang, J. Li, X. Song, J. Chen, Y. Guo, X. Sun, S. Wang, Z. Zhang, X. Zhou, and J. Liu, "Traditional Chinese medicine in cancer care: A review of case series published in the Chinese literature," Evid Based Complement Alternate Med. 751046 PMID: 22778776, 2012.
  24. X. Li and C. Ling, "Chinese herbal medicine for side effects of transarterial chemoembolization in liver cancer patients: A systematic review and meta-analysis," Zhong Xi Yi Jue He Xue Bao,(Chinese). PMID: 23257126, vol. 10, pp. 1341-1362, 2012.
  25. G. Dennert and M. Horneber, "Selenium for alleviating the side effects of chemotherapy, radiotherapy and surgery in cancer patients," Cochrane Database Syst Rev. July19: CD005037, p. 3, 2006.
  26. V. Wagh, "Propolis: A wonder bees product and its pharmacological potentials," Adv Pharmacol Sci. 308249, 2013.
  27. A. Tipping and J. Melo, "Imatinib mesylate in combination with other chemotherapeutic drugs. In vitro studies," Semin Hematol, vol. 40, pp. 83-91, 2003.
  28. D. Lu, T. Lu, and S. Cao, "Drug combinations in cancer treatment," Clinical Experimental Pharmacology, vol. 3, p. 134, 2013.
  29. D. Lu, T. Lu, and H. Wu, "Personalized cancer therapy, a perspective," Clinical Experimental Pharmacology, vol. 4, p. 153, 2014.
Da-Yong Lu , Ting-Ren Lu , Jin-Yu Che , Hong-Ying Wu (2014). Old Theories Revisited on Cancer Assistant Therapy. International Journal of Medical and Health Sciences Research, 1(5): 50-57. DOI:
The causes of cancer deaths are multi-factorials in clinics. Despite the rapid advancement of cancer treatments, many other pathological factors discovered more than half century can also be the targets of cancer therapy. Apart from direct causes from tumor progressions and metastases, many clinical complications or psychiatry factors will more or less speed up these pathogenesis processes of cancer patients, even lost of cancer patients’ life. Based on above-mentioned factors, many types of assistant therapies are designed to counter many harmful clinical complications happening in cancer patients. This mini-review offers the panorama of those therapies, addresses and discusses the history and present advancements. Many key factors and efforts and their future impacts are outlined and highlighted.
Contribution/ Originality